Novo Nordisk A/S (NYSE:NVO) is Hussman Strategic Advisors Inc.’s 4th Largest Position

Hussman Strategic Advisors Inc. raised its position in Novo Nordisk A/S (NYSE:NVO) by 25.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 63,000 shares of the company’s stock after purchasing an additional 12,600 shares during the quarter. Novo Nordisk A/S makes up approximately 1.6% of Hussman Strategic Advisors Inc.’s holdings, making the stock its 4th biggest position. Hussman Strategic Advisors Inc.’s holdings in Novo Nordisk A/S were worth $5,419,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Center for Financial Planning Inc. raised its holdings in shares of Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock valued at $25,000 after purchasing an additional 123 shares in the last quarter. Daiwa Securities Group Inc. acquired a new position in Novo Nordisk A/S during the third quarter worth $28,000. Capital Performance Advisors LLP bought a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at approximately $42,000. Albion Financial Group UT lifted its stake in shares of Novo Nordisk A/S by 121.4% in the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after buying an additional 278 shares during the last quarter. Finally, Sound Income Strategies LLC lifted its position in Novo Nordisk A/S by 82.1% during the 4th quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock worth $46,000 after acquiring an additional 243 shares during the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have commented on NVO. Morgan Stanley assumed coverage on Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Finally, BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Stock Up 1.3 %

NYSE:NVO opened at $83.38 on Thursday. Novo Nordisk A/S has a 1 year low of $77.82 and a 1 year high of $148.15. The stock has a 50-day moving average price of $86.89 and a two-hundred day moving average price of $108.66. The stock has a market cap of $374.18 billion, a price-to-earnings ratio of 25.34, a PEG ratio of 0.88 and a beta of 0.45. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, equities analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be issued a $0.7874 dividend. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 21.88%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.